Non-Polyamine Transport Inhibitors for Selective Polyamine Uptake Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing polyamine-based polyamine transport inhibitors have limitations in terms of significant off-target effects and rapid clearance times, making them ineffective in inhibiting polyamine uptake and intracellular trafficking in cancer cells, as cancers often circumvent polyamine biosynthesis inhibition by importing extracellular polyamines.
Innovation Solution
Development of non-polyamine based polyamine transport inhibitors (PTIs) that selectively inhibit specific modes of polyamine import, reducing off-target effects and increasing drug potency and therapeutic effectiveness.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If polyamine-based polyamine transport inhibitors are used, then polyamine uptake inhibition is achieved, but off-target effects increase and clearance time decreases
Solution Approach 1:
The patent changes the chemical structure parameters of the inhibitor by using non-polyamine based scaffolds (such as heterocyclic compounds, biphenyl structures, and other novel molecular frameworks) instead of traditional polyamine structures. This structural parameter change allows the inhibitor to maintain binding affinity for the polyamine transporter while reducing off-target interactions, thereby resolving the contradiction between effectiveness and harmful effects
Solution Approach 2:
The patent creates molecular copies or analogs of polyamines that can bind to the polyamine transporter but lack the problematic properties of natural polyamines. These synthetic compounds replicate the essential binding features needed for transporter inhibition while eliminating the off-target effects associated with polyamine-based inhibitors, thus achieving selective inhibition with improved safety profile
2Reliability
If polyamine-based polyamine transport inhibitors are used, then polyamine uptake inhibition is achieved, but drug clearance time decreases
Solution Approach 1:
The patent modifies pharmacokinetic parameters by designing non-polyamine based structures with altered physicochemical properties (such as lipophilicity, molecular weight, and metabolic stability). These parameter changes result in improved drug half-life and reduced clearance rates, allowing the inhibitor to maintain effective concentrations for longer periods without requiring frequent dosing
3Reliability
If high doses of DFMO are used to inhibit ODC, then polyamine biosynthesis is inhibited, but tumor escape pathways are activated through increased polyamine import
Solution Approach 1:
The patent introduces a second agent (polyamine transport inhibitor) that acts as an intermediary to block the escape pathway. While DFMO inhibits polyamine biosynthesis, the PTI simultaneously blocks extracellular polyamine import, preventing the tumor from using alternative sources of polyamines. This dual-blocking strategy eliminates the tumor's adaptability to overcome DFMO treatment alone
Data Source
AI summary
Various embodiments relate to compounds and methods useful for preventing or treating a cancer in a subject. The method may include administering to a subject a composition according to any of the embodiments described herein in an amount effective to inhibit metastatic activity or tumor growth in the subject.